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The aim of the study was to assess the frequency and predisposing factors of colonization of upper respiratory tract by Gram-
negative rods (GNRs) in chronic lymphocytic leukemia (CLL) patients. Antimicrobial susceptibility of the isolated strains was
determined. A signiﬁcantly higher frequency of GNR colonization in CLL patients was observed (36.7%) in comparison to healthy
volunteers (8.3%). GNR isolates mainly belonged to the Enterobacteriaceae family. Three isolates of GNR demonstrating presence
ofAmpCβ-lactamasesandoneESBL-producingstrainwereobtainedfromCLLpatients.GNRcolonizationratewashigheramong
CLL patients with lower level of IgG in serum (P = 0.017), with higher number of neutrophils (P = 0.039) or higher number of
lymphocytes in serum (P = 0.053). The longer the time elapsed since diagnosis, the higher the frequency of GNR colonization
observed. Multivariate analysis showed importance of the Rai stage, number, and type of infections as independent predictors of
GNR colonization in CLL patients.
1.Introduction
Infectious complications are still one of the major causes of
morbidity and mortality in patients with chronic lympho-
cyticleukemia(CLL).Infectionsaﬀectmainlytherespiratory
tract, skin, or urinary tract. The most common respiratory
infections are acute and chronic sinusitis, otitis media, and
pneumonia. In the past pneumonia was caused mainly by
Streptococcus pneumoniae, but with current chemotherapeu-
tic regimens, the spectrum of pathogens includes Gram-neg-
ative rods (GNR), Nocardia species, Legionella species, and
Pneumocystis carinii [1]. An increase in infections caused by
GNR, particularly bacteremia and pneumonia, may reﬂect
more advanced disease and profound myelosuppression in
these patients [2].
The epithelial surfaces of the upper respiratory tract are
continuously exposed to a wide variety of commensal and
potentially pathogenic microorganisms, but the density and
composition of colonization need to be controlled by the
host [3]. In addition to acting as a physical barrier, epi-
thelial cells respond to speciﬁc microbial products with
the generation of signals, such as cytokines, that trigger
inﬂammation. Colonization of the upper respiratory tract
by pathogens is often the ﬁrst step in a multifactorial process
leading to disease. About 80% of CLL patients will sustain
infectious complications during their disease, and
50–60% of patients will die due to infection [4]. The
major risk factors for infection in these patients are immune
defects that are inherent to the primary disease process
and therapy-related immunosuppression. Refractory CLL
patients subjected to allogenic hematopoietic cell trans
plantation (allo-HCT) also have a particularly high
incidence of infections compared to allo-HCT recipients
with other lymphoid malignancies [5, 6] Disease- and
therapy-related immune defects include hypogammaglo
bulinemia, as well as perturbations in cell-mediated2 The Scientiﬁc World Journal
immunity, complement activity, and neutrophil function
[4, 7].
Theaimofthisstudywastoassessthefrequencyandpre-
disposing factors of colonization of upper respiratory tract
by GNR in previously untreated CLL patients. Antimicrobial
susceptibility of the isolated strains was determined. To the
best of our knowledge, the present study is the ﬁrst report
analyzing this issue.
2.MaterialandMethods
2.1. Patients. This prospective study included 30 previously
untreated patients with CLL and 24 healthy volunteers at-
tending the Department of Clinical Immunology, Medical
University of Lublin, from March to August 2011. Informa-
tion regarding baseline characteristics, stage according to the
Rai staging system [8], hematological tests results, and num-
ber and types of infections per year (upper or lower respira-
tory tract infections, skin infections) were determined for
CLL patients to analyze risk factors of upper respiratory
colonization by GNR in this group (Table 1).
2.2. Microbiological Procedures. Throat and nasal specimens
were taken using sterile alginate-tipped swabs from each of
the patients during control visit in clinical health care sett-
ings. Swabs were placed directly into Stuart’s trans-medium,
and samples were delivered to the laboratory, where speci-
mens were streaked onto nonselective medium (blood agar)
and selective medium (MacConkey agar). Plates were incu-
batedfor24–48hat35◦Cunderaerobicconditions. Presence
of GNR in sample from nostrils and/or throat was called
colonization. The identiﬁcation of isolates was determined
using Api 20E or Api 20NE as appropriate. Antimicrobial
susceptibility of the isolates was tested by the disc diﬀusion
method according to the European Committee on Antimi-
crobial Susceptibility Testing recommendations (EUCAST
2011). ESBL production screening was detected by double-
disk synergy test [9].
2.3. Flow Cytometric Analysis. Peripheral blood (PB) spec-
imens were obtained from 30 CLL patients and was taken
to 10mL tubes with an EDTA anticoagulant. All PB samples
were stained for ZAP-70 protein expression and CD38 anti-
gen expression, as described previously [10]. A cut-oﬀ point
for ZAP-70 positivity was ≥20%, for CD38 positivity was
≥30% [11] and for CD25 positivity in leukemic cells
was ≥20%. Three-color immunoﬂuorescence analyses were
performed using a FACS Calibur ﬂow cytometer (Becton
Dickinson) equipped with 488nm argon laser. A minimum
of 10,000 events was acquired and analyzed using Cel-
lQuest Software. Mean ﬂuorescence intensity (MFI) and the
percentage of cells expressing surface markers were analyzed.
The cells were phenotypically characterised by incubation
(20min in the dark at a room temperature) with combina-
tion of relevant ﬂuorescein-isothiocyanate- (FITC-), phyco-
erythrin- (PE-), and CyChrome-labeled monoclonal anti-
bodies (mAbs). Immunoﬂuorescence studies were perform-
ed using a combination of the following mAbs: CD3
FITC/CD19 PE, CD8 FITC/CD4 PE, CD25 CyChrome, and
CD69 CyChrome. An acquisition gate was established based
on FSC and SSC that excluded dead cells and debris. Isotype-
matched antibody was used to verify staining speciﬁcity and
as a guide for setting markers used to delineate positive and
negative populations.
2.4. Statistical Analysis. Data processing and analysis were
performed using Statistica 7.0 PL software, StatSoft Inc.
The results are expressed as percentage and mean ± SD.
Continuous variables were compared using a nonparametric
test(U Mann-Whitney test) orparametric Student t-testand
categorical variables by Chi-square or the Fisher exact test, as
appropriate. Relative risks (RRs) and their 95% conﬁdence
intervals (CIs) were calculated. Statistical signiﬁcance was set
at P<0.05. Logistic regression was performed to evaluate
the risk factors associated with GNR colonization. Potential
predictor variables for model entry were identiﬁed using
univariate analysis. Regression models were controlled for
the eﬀects of confounding variables. Results of the logistic
regression analysis are reported as adjusted odds ratio (OR)
with 95% CI.
3. Results
A total of 108 samples obtained from upper respiratory tract
of 54 persons (30 patients with CLL and 24 healthy volu-
nteers) were bacteriologically examined. Colonization by
GNR was observed in 24.1% of the studied persons. A
signiﬁcantly higher frequency of GNR colonization in CLL
patients (36.7%) was observed in comparison to healthy
volunteers (8.3%). This diﬀerence was statistically signiﬁcant
(P = 0.02; RR 4.4; 95%CI 1.1–18.0).
The overall 16 isolates of GNR (from 3 patients, 2 dif-
ferent species of GNR were isolated) were cultured: 8
(50%) isolates were obtained from throat, 6 (37.5%) from
nostrils, and 2 (12.5%) isolates colonized both throat and
nostrils. Species of GNR isolates are shown in Table 2.G N R
isolates mainly belonged to the Enterobacteriaceae family,
and only 1 isolate, Pseudomonas aeruginosa,b e l o n g e dt o
nonfermentative Gram-negative rod—Pseudomonadaceae.
ESBL-producing isolate, Proteus vulgaris, was obtained
fromoneCLLpatient.Fourisolates,Citrobacterkoseri,Serra-
tiamarcescens,andtwoisolatesofHafniaalvei,demonstrated
the presence of AmpC β-lactamases (Table 2), three of them
were obtained from CLL patients.
The selected factors were tested for their association with
GRN colonization in CLL patients. At the ﬁrst, in univariate
analysis, the diﬀerences in hematological parameters of
colonized by GNRs and noncolonized patients turn out
to be statistically signiﬁcant (Table 3). Colonization rate
was higher among CLL patients with lower level of IgG in
serum (P = 0.017) and patients with higher number of
neutrophils (P = 0.039) or those who had higher number
of lymphocytes in serum (P = 0.053). It was shown that
the longer the time elapsed since diagnosis in CLL patients,
the higher the frequency of GNR colonization observed
(P = 0.025). Multivariate analysis showed importance ofThe Scientiﬁc World Journal 3
Table 1: Selected demographic, clinical, and laboratory parameters of the CLL patients.
Parameter No. of patients (%) Mean±SD Range
Age 60.47 ±8.3 43–80
Gender:
Males 12 (40)
Females 18 (60)
The Rai stage:
0 8 (26.7)
1 8 (26.7)
2 11 (36.7)
3 3 (10.0)
Period from diagnosis (years) 5.0 ±3.30 – 1 1
No. of infections per year 4.4 ±3.11 – 1 1
Type of infection:
URTIs 12 (40.0)
LRTIs 5 (16.7)
URTs+LRTIs 6 (20.0)
LTRIs+skin infections 1 (3.3)
URTIs+LRTIs+skin infections 2 (6.7)
Lymphocytes (%) 72.1 ±11.8 48.3–89.3
Lymphocytes (103/mm3) 27.2 ±23.3 5.3–90.9
Neutrophils (%) 22.1 ±17.4 3.5–91.0
Neutrophils (103/mm3) 6.1 ±4.9 1.2–20.5
IgA (mg/dL) 153.0 ±103.2 3–380
IgG (mg/dL) 774.3 ±303.1 320–1616
IgM (mg/dL) 64.3 ±52.8 4–220
CD3+ cells (%) 13.8 ±11.9 1.2–56.2
CD19+ cells (%) 80.6 ±13.5 35.2–96.8
CD5+CD19+ cells (%) 74.6 ±20.2 45–96.7
CD19+ZAP70+ cells (%) 16.2 ±13.1 1.7–45.3
Negative 21 (75.0)
Positive 7 (25.0)
CD19+CD38+ cells (%) 17.7 ±18.7 0.3–56.7
Negative 20 (71.4)
Positive 8 (28.6)
ZAP70 expression in relation to CD38 expression on B lymphocytes
ZAP70 (−), CD38 (−) 18 (64.3)
Z A P 7 0( + ) ,C D 3 8( + ) 5( 1 7 . 9 )
Z A P 7 0( + ) ,C D 3 8( −)2 ( 7 . 1 )
ZAP70 (−), CD38 (+) 3 (10.7)
CD19+CD25+ cells (%) 39.0 ±25.5 1.9–89.8
Negative 7 (25.0)
Positive 21(75.0)
CD19+CD69+ cells (%) 23.4 ±18.3 0.4–60.8
CD3+CD25+ cells (%) 20.5 ±12.5 2.4–52.8
CD3+CD69+ cells (%) 6.2 ±7.3 0.5–29.3
CD3+CD4+cells (%) 7.5 ±6.4 0.8–33.1
CD3+CD8+cells (%) 7.0 ±6.1 0.5–24.2
CD4+ to CD8+ cells ratio 1.4 ±0.7 0.3–3.2
CD4+CD8+cells (%) 0.5 ±0.7 0.03–3.6
URTIs: upper respiratory tract infections, LRTIs: lower respiratory tract infections.4 The Scientiﬁc World Journal
Table 2: Gram-negative rods isolated from upper respiratory tract from examined patients and their resistance patterns.
Species No. of isolates Resistance pattern (no. of isolates)
Escherichia coli 4S ( 4 )
Klebsiella pneumoniae subsp. pneumoniae 2 S (1); Am (1)
Klebsiella oxytoca 2 Am Pip Tic Tob (1); Am Pip Tic (1)
Serratia marcescens 1 Am Amc Pip Tzp Tic Tim Cxm Ctx Caz Te
Proteus vulgaris 1 Am Amc Pip Tzp Tic Tim Cxm Ctx Caz Fep Atm Ipm Te Sxt
Proteus mirabilis 1C x m
Citrobacter koseri 1 Am Amc Pip Tzp Tic Tim Cxm Ctx Caz
Hafnia alvei 1 Am Amc Pip Tzp Tic Tim Cxm Ctx Caz
Pseudomonas aeruginosa 1A m c T e S x t
Am, ampicillin; Amc, amoxycillin/clavulanate acid; Pip, piperacillin; Tzp, piperacillin/tazobactam; Tic, ticarcillin; Tim, ticarcillin/clavulanate acid; Cxm, cefu-
roxime; Ctx, cefotaxime; Caz, ceftazidime; Fep, cefepime; Atm, aztreonam; Ipm, imipenem; Te, tetracycline; Sxt, trimetoprim/sulfamethoxazole.
the Rai stage, number of infections per year, and type of in-
fections as independent predictors of upper respiratory GNR
colonization in CLL patients (Table 4).
4. Discussion
Colonization of the respiratory tract by Gram-negative bac-
teria is a frequent cause of infection, mainly pneumonia.
In healthy individuals, the upper respiratory tract is not
usually colonized by GNR [12]. Prevalence of GNR coloni-
zation increases with the presence of several serious illness-
es.Johansonetal.[13]reportedthedirectrelationoforopha-
ryngeal GNR colonization and the severity of underlying ill-
ness of the population studied. Colonization rates of three
studied groups, healthy person, moderately ill patients, and
patients classiﬁed as “moribund”, were 2%, 16%, and 57%,
respectively. In our study, about 8% of healthy volunteers
and about 37% of CLL patients were colonized by GNR. This
data are similar to those obtained by Los et al. [14]i np a -
tients with lung cancer. Also similar results were shown by
Ortqvist et al. [15] who conducted study on patients with
secondary infection during hospital treatment. It was shown
that35%patientswerecolonizedbyGNRduringhospitaliza-
tion, and this colonization was a negative prognostic factor,
associated with higher mortality, doubled length of hospital
stay, and slower recovery. During hospitalization, patient’s
microﬂora is constantly changing depending on the environ-
mental condition and applied treatment. Fermentative and
nonfermentative GNR which are often present in hospital
microﬂora colonize patients successfully. Patients tested in
our study were untreated and not hospitalized of any cause,
so frequency of GNR colonization seems to be closely
related only to the patient status. Niederman [12]s u g g e s t e d
that colonization of the oropharynx by Gram-negative
bacteria is a marker for critically ill patients who have
multiple deﬁciencies in the host defense system of their res-
piratory tract, and these patients are also likely to have other
impairments in the cellular and humoral response to bacte-
rial invasion.
There is no data related to impact and signiﬁcance of
colonization in upper respiratory tract CLL patients by GNR
todevelopinfectionduringthecourseofthedisease.Patients
with CLL have defected humoral and cellular immunity,
damages in the complement system, and variable neutro-
penia that contribute to the high rate of infections. Hypo-
gammaglobulinemia and advanced disease are major pre-
disposing factors described elsewhere [1, 4, 16]. In
patients having early-stage untreated CLL, risk of infections
may be related mainly to hypogammaglobulinemia [2].
Hypogammaglobulinemia is one of the two routinely mea-
sured immune defects associated with CLL (the other one
is neutropenia), which correlates with disease duration and
stage. Its association with infection in CLL patients is well
known [2, 4, 17]. In our study, lower level of IgG in serum
and higher Rai stage of CLL were related to higher frequency
of colonization by GNR. Additionally, statistically signiﬁcant
predictor for GNR colonization was longer period from
diagnosis of CLL in studied patients.
A signiﬁcant correlation between low IgA level and the
risk of infections was demonstrated in some reports [18, 19].
In our patients with CLL, lower level of IgA in the group
of GNR colonized patients in comparison to noncolonized
group was observed, but this diﬀerence was not statistically
signiﬁcant.
Despite known defects in cell-mediated immunity and
complement activity, no correlation has been proved bet-
ween these defects and the occurrence of infectious compli-
cationorbacterialcolonization.Inourstudy,norelationbet-
ween GNR colonization and particular cell subsets was ob-
served. The T-cell abnormalities found in CLL patients are
thoughttoincreasetheriskofinfectionandhamperimmune
recognitionandeliminationofleukemiccells.Bonyhadietal.
[20] suggested that in vitro engagement of CD3 and CD28
corrects T-cell defects in CLL. Researchers found that peri-
pheral blood mononuclear cells incubated with anti-CD3
and anti-CD28 monoclonal antibodies conjugated to super-
paramagnetic beads for 12–14 days caused a 1400-fold
increase in T-cell numbers. Activated T cells expressed high
levels of CD25, CD54, CD137, and CD154 and produced
IFN-γ,T N F - α, and GM-CSF. The mean T-cell composition
of cultures increased from around 6% to >90%. Aforemen-
tioned authors initiated also a clinical trial to test the poten-
tial therapeutic eﬀects of T cells activated using this ap-
proach in patients with CLL. Thus, infection rates may be
diminished; however, this method will probably not aﬀect
GNR colonization of nasopharynx. In patients with ShigellaThe Scientiﬁc World Journal 5
Table 3: The association between Gram-negative rods colonization and selected demographic, clinical or laboratory parameters in CLL
patients.
Predictors No. of patients or mean±SD P; OR (95%CI)
GNR colonized (n = 11) Noncolonized (n = 19)
Age 58.2 ±6.35 9 .9 ±9.80 . 7 3
Males 2 (18.2) 10 (52.6) 0.12; 1.7 (1.0–3.0)
Rai stage: 0.03∗
0 1 (9.1) 7 (36.8)
1 1 (9.1) 7 (36.8)
2 7 (63.6) 4 (21.1)
3 2 (18.2) 1 (5.3)
Period from diagnosis (years) 6.8 ±2.13 .9 ±3.3 0.025∗
No. of infections per year 3.9 ±1.93 .6 ±2.20 . 2 6
Types of infections 0.22
Lymphocytes (%) 71.1 ±11.97 1 .6 ±11.60 . 8 3
Lymphocytes (103/mm3)3 9 .2 ±23.51 6 .4 ±9.0 0.053
Neutrophils (%) 20.0 ±11.71 9 .9 ±11.30 . 8 5
Neutrophils (103/mm3)7 .5 ±4.05 .3 ±5.3 0.039∗
IgA (mg/dL) 90.3 ±45.3 146.4 ±100.20 . 2 1
IgG (mg/dL) 563.3 ±217.5 940.0 ±307.5 0.017∗
IgM (mg/dL) 31.5 ±14.86 2 .1 ±50.60 . 9 5
CD3+ cells (%) 13.4 ±5.31 1 .7 ±7.90 . 8 6
CD19+ cells (%) 80.5 ±7.48 4 .1 ±8.90 . 6 0
CD5+CD19+ cells (%) 18.9 ±8.87 2 .5 ±24.60 . 5 5
CD19+ZAP70+ cells (%) 14.5 ±14.51 8 .3 ±14.10 . 7 7
Positive/negative 3/4 (42.9) 7/14 (33.3) 0.67; 1.5 (0.3–1.6)
CD19+CD38+ cells (%) 21.3 ±17.11 8 .2 ±19.10 . 3 8
Positive/negative 4/4 (50.0) 6/14 (30.0) 0.40; 2.3 (0.4–12.6)
CD19+CD25+ cells (%) 26.2 ±23.44 4 .2 ±27.10 . 1 4
Positive/negative 8/13 (38.1) 2/5 (28.6) 1.0; 1.5 (0.2–9.9)
CD19+CD69+ cells (%) 16.0 ±13.12 1 .6 ±20.70 . 8 8
CD3+CD25+ cells (%) 18.9 ±8.81 8 .5 ±8.30 . 7 2
CD3+CD69+ cells (%) 2.6 ±1.37 .6 ±7.90 . 5 5
CD3+CD4+cells (%) 8.3 ±3.26 .1 ±3.30 . 1 9
CD3+CD8+cells (%) 7.3 ±4.17 .3 ±6.10 . 9 8
CD4+-to-CD8+ cells ratio 1.3 ±0.71 .3 ±0.80 . 9 5
CD4+CD8+cells (%) 0.4 ±0.10 .4 ±0.41 . 0
∗P < 0.05.
Table 4: Logistic regression analysis of factors predictive of GNR
colonization in CLL patients.
Predictors OR (95%CI) P
Rai stage 8.1 (1.4–47.6) 0.014
No. of infections per year 4.2 (1.1–15.8) 0.027
Types of infections 0.06 (0.005–0.7) 0.018
infection, Islam et al. [21] found evidence for sequential T-
cell activation, as shown by increased proportions of CD25
and CD4+ cells, HLA-DR and CD38 on CD8+ cells, and
CD54 on CD4+ and CD8+ cells. Neither the proportion of
CD3 T cells in peripheral blood mononuclear cells nor the
CD3 MFI was signiﬁcantly diﬀerent in the group of infected
individuals than it was in controls, and our observations are
similar to theirs. In the research of Stuller et al. [22], it was
demonstrated that CD25(+) cells induce anergy in CD25(−)
cells in response to Helicobacter pylori infection but are
not required to maintain hyporesponsiveness. In addition,
CD25(+) cells are able to suppress previously activated
CD25(−) cells when responding to this bacteria challenge in
vivo. The lack of GNR colonization inﬂuence on activation
markers in CLL patients may be due to disease-dependent
cell dysfunction or bacteria-induced immunosuppression.
We performed also an analysis of principal CLL prognos-
tic factors in order to determine if the percentage of ZAP-
70+ and CD38+ cells diﬀer in colonized and not colonized
patients. High levels of CD38 and ZAP-70 expression [11,
23] and unmutated immunoglobulin (Ig)VH genes [11, 24]6 The Scientiﬁc World Journal
are associated with aggressive disease. Francis et al. [25]
found that older age, clinical stage of the disease, unmutated
IgVH gene status, and positive CD38 status were associated
with a signiﬁcantly shorter time to ﬁrst infection. Authors
also maintained that patient age, disease stage, CD38 ex-
pression, and IgVH mutation status had a signiﬁcant impact
on infection-related mortality. Our study revealed that the
Rai stage correspond with potentially pathogenic bacteria
colonization of upper respiratory tract, so the patients pre-
sent higher infection risk. Higher number of lymphocytes
was observed in our study as the predictor of GNR coloni-
zation in CLL patients and the amount of these cells, espe-
cially lymphocyte doubling time, are predictors of a shorter
treatment-free survival [26]. Therefore, we propose to ad-
ministrate to the colonized individuals prophylaxis with the
use of appropriate antibiotics.
Our data indicate that patients colonized by GNR had
signiﬁcantly higher absolute neutrophil count than noncolo-
nized ones. Quantitative and qualitative defects of neutro-
phils are observed in CLL patients, but their total number
is normal or slightly decreased in untreated patients and
may decline further with disease progression, due to marrow
inﬁltration and use of myelosuppressive therapy. Although
neutrophil function seems to be normal in CLL patients,
enzyme deﬁciencies in the neutrophils of untreated patients
leading to inhibition of neutrophil phagocytic and bacterici-
dal activity were demonstrated [4].
A better determinant of association between CLL and
upper respiratory bacterial colonization should be an assess-
ment of the mucosal immune defects. We did not analyse
levels of mucosal (salivary) IgA, IgG, and IgM in tested CLL
patients, but in preliminary report of other authors no asso-
ciations were found between salivary immunoglobulin levels
and infections [17].
Asexpected,inourstudyinfectionswerefrequentinCLL
patients, but we were not able to ﬁnd a correlation between
speciﬁc colonized strain and speciﬁc infection. However,
higher number of infections and type of infection were
shown as independent predictors of GNR colonization in
CLL patients. (Upper respiratory GNR colonization is not
the synonymous of infection but indicates the higher risk of
its development in immunodeﬁcient patients especially.)
Changing spectrum of bacterial pathogens in infected
patients with neutropenia and cancer over the past 3 decades
was observed. In most medical centers, Gram-negative bac-
teria, for example, Escherichia coli, Pseudomonas aeruginosa,
and Klebsiella spp., were responsible for 60%–70% of infec-
tions. Recently, a clear shift in these infecting organisms was
documented,andmainlyGram-positivecocciwereresponsi-
ble for bacteremia in patients with neutropenia. Zinner [27]
suggested that some of the factors believed responsible for
this shift include oral mucositis as a result of increasingly po-
tent chemotherapeutic regiments, profound and prolong-
ed neutropenia, and factors connected to hospitalization and
therapy. Patients tested in our studied were untreated due to
CLL so none of them was exposed to mentioned factors and
high rate of GNR colonization was observed.
In our study, 4 isolates of GNRs demonstrating presence
of extended-spectrum β-lactamases were obtained from
CLL patients—ESBL-producing strain, and three AmpC-
presented strains. AmpC β-lactamases are clinically impor-
tantcephalosporinasesencodedonthechromosomeinmany
Enterobacteriaceae and a few other organisms, and they
mediated resistance to multiple agents, making the selection
of an eﬀective antibiotic therapy diﬃcult. β-lactam/β-lac-
tamase inhibitor combinations and most penicillins and ce-
phalosporins should be avoided because of in vitro resistance
and the potential for AmpC induction or selection of high-
enzyme-level mutants [28]. ESBLs are enzymes that med-
iate resistance to extended-spectrum (third generation)
cephalosporins of third generation (e.g., ceftazidime, cefo-
taxime, and ceftriaxone) and monobactams (e.g., aztre-
onam) but do not aﬀect cephamycins (e.g., cefoxitin and
cefotetan) or carbapenems (e.g., meropenem or imipenem)
[29]. ESBL-producing organisms pose a major problem for
clinical therapeutics. The incidence of β-lactamases-pro-
ducing strains among clinical isolates has been steadily in-
creasing over the past decade resulting in limitation of thera-
peutic options. Initially restricted to hospital acquired infec-
tions, they have also been isolated from infections in out-
patients. Major outbreaks involving ESBL strains have been
reported all over the world, thus making them emerging
pathogens.
5. Conclusion
CLL patients are not a homogeneous population in respect
of infectious morbidity and mortality. Therefore, awareness
of risk factors predisposing to pathogens colonization, for
example, upper respiratory GNR colonization, allows to
identify group of patients which should be considered for
Ig or antibiotic prophylaxis. Moreover, knowledge about
antibioticresistanceofthecolonizingpathogensisimportant
to propose not only optimal antibiotic prophylaxis scheme
but also empiric and targeted therapy with greater likelihood
of clinical success.
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